PMID- 27919979
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20181202
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 12
DP  - 2016 Dec
TI  - Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers 
      with Squamous NSCLC: The TALISMAN Randomized Trial.
PG  - 6535-6540
AB  - BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with 
      recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized 
      trial evaluates the combination of erlotinib with docetaxel in the second-line 
      therapy of ex-smoker males with advanced squamous non-small cell lung cancer 
      (NSCLC). PATIENTS AND METHODS: Patients received erlotinib 150 mg/day (arm A; 
      n=36) or docetaxel 75 mg/m(2) on day 1 of each 3-week cycle and erlotinib 150 
      mg/day on days 2-16 of each cycle (arm B; n=38). The primary end-point was 
      progression-free rate (PFR) at 6 months. RESULTS: The study was prematurely 
      interrupted due to slow enrolment. Three (8.3%) patients in arm A and 3 (8.1%) in 
      arm B remained progression-free at 6 months. Median progression-free survival 
      (PFS) was 2.3 months in arm A and 2.8 months in arm B. Median overall survival 
      (OS) was 5.6 and 8.9 months, respectively. Overall, 77.8% of patients in arm A 
      and 89.2% in arm B experienced treatment-related adverse events (AEs). 
      CONCLUSION: Results do not support further investigation of the combination of 
      erlotinib and docetaxel in this setting.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Gridelli, Cesare
AU  - Gridelli C
AD  - Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy 
      cgridelli@libero.it.
FAU - Chella, Antonio
AU  - Chella A
AD  - University Hospital, Pisa, Italy.
FAU - Valmadre, Giuseppe
AU  - Valmadre G
AD  - ASST Valtellina e Alto Lario, Sondrio, Italy.
FAU - Allegrini, Giacomo
AU  - Allegrini G
AD  - Az-USL 5 Pisa, Pisa, Italy.
FAU - Brighenti, Matteo
AU  - Brighenti M
AD  - Cremona Hospital, Cremona, Italy.
FAU - Bidoli, Paolo
AU  - Bidoli P
AD  - San Gerardo Hospital, Monza, Italy.
FAU - Rossi, Antonio
AU  - Rossi A
AD  - Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
FAU - Maione, Paolo
AU  - Maione P
AD  - Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
FAU - Migliorino, Maria Rita
AU  - Migliorino MR
AD  - San Camillo Hospital, Roma, Italy.
FAU - Ricciardi, Serena
AU  - Ricciardi S
AD  - San Camillo Hospital, Roma, Italy.
FAU - DE Marinis, Filippo
AU  - DE Marinis F
AD  - Thoracic Oncology Division, European Institute of Oncology (IEO), Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Disease-Free Survival
MH  - Docetaxel
MH  - Erlotinib Hydrochloride/*administration & dosage
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - *Smoking
MH  - Taxoids/*administration & dosage
OTO - NOTNLM
OT  - Combination therapy
OT  - NSCLC
OT  - docetaxel
OT  - erlotinib
OT  - males
OT  - second-line treatment
OT  - smokers
EDAT- 2016/12/07 06:00
MHDA- 2017/01/31 06:00
CRDT- 2016/12/07 06:00
PHST- 2016/08/10 00:00 [received]
PHST- 2016/09/27 00:00 [revised]
PHST- 2016/10/01 00:00 [accepted]
PHST- 2016/12/07 06:00 [entrez]
PHST- 2016/12/07 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
AID - 36/12/6535 [pii]
AID - 10.21873/anticanres.11255 [doi]
PST - ppublish
SO  - Anticancer Res. 2016 Dec;36(12):6535-6540. doi: 10.21873/anticanres.11255.